Avenacy Launches Prochlorperazine Edisylate Injection, USP in U.S.

Avenacy, a specialty pharmaceutical company dedicated to providing essential injectable medications, has recently introduced Prochlorperazine Edisylate Injection, USP, to the U.S. market. This new product is a generic alternative to COMPAZINE® and has received approval from the U.S. Food and Drug Administration (FDA). Prochlorperazine Edisylate Injection, USP, is primarily used to manage severe nausea and vomiting and treat schizophrenia. However, it is not effective for managing behavioral issues in patients with mental retardation.

The product is available in 10 mg/2 mL (5 mg per mL) 10-pack multi-dose vials. Avenacy is committed to patient safety and efficient care, which is reflected in their unique packaging and labeling designed for accurate medication selection.

Starting this week, Avenacy will begin distributing Prochlorperazine Edisylate Injection, USP, to wholesale partners. The company relies on a global network of development and contract manufacturing partners that have passed FDA inspections based on current Good Manufacturing Practice (cGMP) standards.

Prochlorperazine Edisylate Injection, USP, achieved U.S. sales of around $15 million for the twelve months ending in June 2023. However, it is important to note a serious warning associated with the use of antipsychotic drugs in elderly patients with dementia-related psychosis. These patients are at a higher risk of death when treated with such medications. Studies have shown that the death rate in drug-treated patients is 1.6 to 1.7 times higher than in those given a placebo. The causes of death varied but were mostly cardiovascular or infectious. Conventional antipsychotic drugs, like Prochlorperazine Edisylate Injection, USP, might also increase mortality in these patients. It is unclear whether this increased risk is due to the medications or the patients' characteristics. Therefore, Prochlorperazine Edisylate Injection, USP, is not approved for treating dementia-related psychosis.

Avenacy, founded in October 2023, is headquartered in Schaumburg, Illinois. The company aims to build a robust pipeline of FDA-approved injectable products to meet the demands of the constantly evolving drug supply chain. With a dedicated team and a commitment to quality and reliability, Avenacy strives to be a trusted provider of essential medications.